English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A validated and robust bioassay is of paramount importance in the various stages of biosimilar development to ensure efficacy, quality and potency. The complement-dependent cytotoxicity assay was validated over six simulated potencies and found specific for rituximab-like antibodies. The bioassay was found robust with linearity parameter R = 0.99, %GCV for precision and accuracy was less than 20% for >40 individual performances. Detailed set of system suitability and sample acceptance criteria was determined. The study may play a key part in the development of written and physical potency reference standards for incorporation in different pharmacopeia for effective biosimilar development and regulation.

Quality Assurance of Rituximab (Anti-CD 20) Antibodies by Potency Testing:Determining the System Suitability Criteria and Sample Acceptance Criteria